Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Lexicon Pharmaceutcl (LXRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 828,922
  • Shares Outstanding, K 106,272
  • Annual Sales, $ 63,210 K
  • Annual Income, $ -120,550 K
  • 60-Month Beta 0.70
  • Price/Sales 12.81
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.21
  • Number of Estimates 2
  • High Estimate -0.18
  • Low Estimate -0.23
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +47.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.20 +55.19%
on 02/28/19
8.39 -3.81%
on 03/13/19
+2.72 (+50.84%)
since 02/20/19
3-Month
4.26 +89.44%
on 01/30/19
8.39 -3.81%
on 03/13/19
+1.13 (+16.28%)
since 12/20/18
52-Week
4.26 +89.44%
on 01/30/19
13.97 -42.23%
on 06/19/18
-0.06 (-0.74%)
since 03/20/18

Most Recent Stories

More News
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Lexicon Pharmaceuticals, Inc. to Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company")(NASDAQ:LXRX) of the April 1, 2019 deadline to...

LXRX : 8.17 (+4.74%)
Lexicon Pharmace Up 38.4% Since SmarTrend Uptrend Call (LXRX)

SmarTrend identified an Uptrend for Lexicon Pharmace (NASDAQ:LXRX) on February 25th, 2019 at $5.52. In approximately 3 weeks, Lexicon Pharmace has returned 38.41% as of today's recent price of $7.64.

LXRX : 8.17 (+4.74%)
Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study

Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.

LXRX : 8.17 (+4.74%)
CELG : 88.73 (-0.38%)
KMDA : 5.86 (-0.51%)
SNY : 45.15 (+0.02%)
(LXRX) Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc. ("Lexicon " or the "Company") (NASDAQ: LXRX)...

LXRX : 8.17 (+4.74%)
Lexicon Pharmaceuticals Announces Dosing of First Patient in TELE-ABC Study, a Phase 2a Clinical Study of Telotristat Ethyl in Biliary Tract Cancer

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today dosing of the first patient in the Telotristat Ethyl for Advanced Biliary Tract Cancer, or TELE-ABC, study, which is a Phase 2a clinical study...

LXRX : 8.17 (+4.74%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX

Pomerantz LLP announces that a class action lawsuit has been filed against Lexicon Pharmaceuticals, Inc. ("Lexicon" or the "Company") (NASDAQ: LXRX) and certain of its officers and directors. The class...

LXRX : 8.17 (+4.74%)
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 42.86% and 24.33%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

LXRX : 8.17 (+4.74%)
Lexicon: 4Q Earnings Snapshot

THE WOODLANDS, Texas (AP) _ Lexicon Pharmaceuticals Inc. (LXRX) on Wednesday reported a loss of $16.8 million in its fourth quarter.

LXRX : 8.17 (+4.74%)
Lexicon Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 13, 2019 / Lexicon Pharmaceuticals, Inc. (NASDAQ: ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 13, 2019, 2018...

LXRX : 8.17 (+4.74%)
Do Options Traders Know Something About Lexicon Pharmaceuticals (LXRX) Stock We Don't?

Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.

LXRX : 8.17 (+4.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade LXRX with:

Business Summary

Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones....

See More

Key Turning Points

2nd Resistance Point 8.29
1st Resistance Point 8.04
Last Price 8.17
1st Support Level 7.52
2nd Support Level 7.25

See More

52-Week High 13.97
Fibonacci 61.8% 10.26
Fibonacci 50% 9.11
Last Price 8.17
Fibonacci 38.2% 7.97
52-Week Low 4.26

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar